Intra-Cellular Therapies Overview
Intra-Cellular Therapies Target Price
Analysts' 12-month price predictions for ITCI.
Share Price
$131.87
Average Target Price
$132.00
0.1% upside
0.1% upside1 analysts in the last 4 months
High: $132 | Low: $132
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2025-01-14 | Piper SandlerDavid Amsellem | $132 | 0.1% upside |  |
| 2024-10-30 | Goldman SachsCorinne Jenkins | $79 |  40.1% downside | |
| 2024-09-05 | Piper SandlerDavid Amsellem | $92 | 30.2% downside | |
| 2024-08-08 | RBC CapitalBrian Abrahams | $106 | 19.6% downside | |
| 2024-08-07 | Goldman SachsCorinne Jenkins | $74 | 43.9% downside | |
| 2024-07-22 | NeedhamAmi Fadia | $100 | 24.2% downside | |
| 2024-06-25 | UBSAshwani Verma | $83 | 37.1% downside | |
| 2024-06-20 | Mizuho SecuritiesGraig Suvannavejh | $100 | 24.2% downside | |
| 2024-06-18 | RBC CapitalBrian Abrahams | $103 | 21.9% downside | |
| 2024-05-07 | RBC CapitalBrian Abrahams | $96 | 27.2% downside | |
| 2024-05-07 | JefferiesAndrew Tsai | $105 | 20.4% downside | |
| 2024-04-23 | Canaccord GenuitySumant Kulkarni | $107 | 18.9% downside | |
| 2024-04-17 | Robert W. BairdJoel Beatty | $103 | 21.9% downside | |
| 2024-04-05 | NeedhamAmi Fadia | $82 | 37.8% downside | |
| 2022-06-13 | UBSAshwani Verma | $75 | 43.1% downside | |
| 2022-04-22 | Piper Sandler | $59 | 55.3% downside | |
| 2022-04-21 | Leerink Partners | $70 | 46.9% downside | |
| 2022-02-17 | Goldman SachsCorinne Jenkins | $64 | 51.5% downside | |